October 2024
The mycobacterium tuberculosis market was estimated at US$ 730.00 million in 2023 and is projected to grow to US$ 1,385.79 million by 2034, rising at a compound annual growth rate (CAGR) of 6% from 2024 to 2034. The increasing incidences of tuberculosis, advances in diagnostic assays, and increasing demand for novel treatments drive the market.
Unlock Infinite Advantages: Subscribe to Annual Membership
Mycobacterium tuberculosis is a bacteria that causes tuberculosis (TB) in humans. TB is an infectious disease that infects the lungs or other tissues. Symptoms of TB include a long-lasting cough, pain in the chest, coughing up blood or sputum, fatigue or weakness, loss of appetite, and weight loss. TB is diagnosed using tuberculin skin tests, blood tests, sputum tests, X-rays, or CT scans. The common treatment drugs for TB include isoniazid, rifampin, ethambutol, pyrazinamide, and rifapentine.
The increasing incidences of TB disease drive the market. TB is the second-leading infectious killer disease after COVID-19 globally. According to the WHO, approximately 10.6 million people globally were reported with TB in 2022, out of which 5.8 million were men, 3.5 million were women, and 1.3 million were children. Additionally, the advent of advanced detection techniques for TB and growing research and development augment the market growth. The rise in multi-drug resistant TB (MDR TB) increases the demand for novel drug discovery, potentiating the market.
The increasing incidences of tuberculosis and deaths have led to the development of early detection and efficient treatment regimens. Several government bodies and private organizations are investing in supporting TB research. The advancements in technology and biotechnology research demonstrate innovations in TB diagnosis. The demand for rapid and accurate detection promotes innovations in diagnostic testing. Novel testing methods such as nucleic acid amplification tests (NAAT) and line probe assays (LPA) are based on PCR techniques. Researchers have also developed novel methods based on gene editing techniques like CRISPR-Cas9 to identify the genes of mycobacterium tuberculosis bacteria. Additionally, advanced technologies like artificial intelligence drive automation in the detection. Computer-aided detection for chest radiographs uses AI to improve sensitivity and specificity.
Patients in rural areas of many countries, especially in lower- and middle-income countries, find it difficult to access high-quality healthcare services. This limits the early detection of TB, thereby hampering efficient treatment of the patients, resulting in slow and insufficient case detection and low cure rates. Additionally, the huge treatment costs limit the affordability of poor people. The treatment cost depends on the severity of the disease, and it ranges from $20,000 to $200,000 annually in the U.S.
North America dominated the mycobacterium tuberculosis market in 2023. The state-of-the-art research and development facilities, increasing incidences of TB, and increasing investments drive the market. There were around 8,331 TB cases in the US and 1,971 TB cases in Canada in 2022. The U.S. reported a 5.9% increase in cases from 2021. The US and the Canadian governments regularly release guidelines on eradicating TB in the region. Each US state has its own TB program. The Division of Tuberculosis Elimination by the CDC funds four Tuberculosis Centers of Excellence for Training, Education, and Medical Consultation for the project period of 2023-2027. The market is also driven by technological advancements and the increasing number of clinical trials. The US is the largest donor to the Global Fund to Fight AIDS, TB, and Malaria. The US funding for 2023 was around $406 million.
Asia-Pacific is anticipated to grow fastest during the forecast period. The rising geriatric population, increasing incidences of TB, and growing research and development activities drive the mycobacterium tuberculosis market. In Japan, around 10,235 cases of TB were reported in 2022. Meanwhile, in South Korea, 20,383 TB cases were reported in 2022. Several government and private programs to eradicate TB also augment the market growth. Programs like the “5-year National TB Control Program” and the “National Tuberculosis Elimination Program” by the China and India Governments promote control and prevention of TB in the nation. Also, the Japan Anti-Tuberculosis Association aims to conduct activities related to the prevention and care of TB and spread awareness regarding the same. In 2022, the Indian Council of Medical Research (ICMR) was the fifth-largest funder of TB research, with an investment of $20 million.
By type, the molecular rapid diagnosis segment led the mycobacterium tuberculosis market in 2023. The demand for point-of-care diagnostics boosts the segment growth. Molecular rapid diagnosis has high diagnostic accuracy for detecting TB and MDR TB. The segment is also attributed to the recommendation by the WHO.
By type, the culture method is projected to grow significantly in the market over the coming years. The culture method is widely used during treatment monitoring and is the most sensitive and specific phenotypic method for detecting mycobacterium tuberculosis.
By application, the hospital segment held a dominant presence in the mycobacterium tuberculosis market. Hospitals are highly preferred as they possess specialized equipment for diagnosis and necessary treatment regimens depending on the patient’s condition. Hospitals have favorable infrastructure and trained professionals to treat the patients. Additionally, favorable reimbursement policies promote segment growth.
By Application, the clinics segment is expected to grow rapidly in the market during the forecast period. Clinics are preferred for the diagnosis and treatment of the initial stages of TB. Easy access and less expensive facilities make it a suitable choice.
By Type
By Application
By Region
October 2024
October 2024
October 2024
October 2024
Deepa has certified the degree of Master’s in Pharmacy in the Pharmaceutical Quality Assurance department from Dr D.Y. Patil College of Pharmacy. Her research is focused on the healthcare industry. She is the author or co-author of four Review Articles, which include Solid dispersion a strategic method for poorly soluble drugs and solubility improvement techniques for poorly soluble drugs, Herbal Drugs Used In Treatment Of Cataracts, Nano sponges And Their Application in Cancer Prevention and Ayurvedic Remedies of Peptic ulcer. She has also published a Research Article on the Formulation and Evaluation of Mucoadhesive Tablets of Miconazole cocrystal which was published in GIS Science Journal Volume 9 Issue 8. Her passion for secondary research and desire to take on the challenge of solving unresolved issues is making her flourish is the in the research sector.